A relatively low dose of MOG35-55/I-Ab dimer (1 μg of the dimer per mouse daily for 4 days) achieved improved symptom-score in the MOG35-55 peptide-induced EAE mouse, indicating that the soluble peptide/MHC dimer may offer another promising therapeutic choice for EAE and MS, as well as other T-cell mediated autoimmune diseases. This evidence concerns the gene HLA-C and myeloid sarcoma.